SEHK:2500

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Venus Medtech (Hangzhou)

Executive Summary

Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. More Details


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Venus Medtech (Hangzhou)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2500 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 2500's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

27.9%

2500

10.9%

HK Medical Equipment

3.5%

HK Market


1 Year Return

109.8%

2500

113.9%

HK Medical Equipment

15.1%

HK Market

Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned 113.9% over the past year.

Return vs Market: 2500 exceeded the Hong Kong Market which returned 15.1% over the past year.


Shareholder returns

2500IndustryMarket
7 Day27.9%10.9%3.5%
30 Day17.7%12.5%12.7%
90 Day26.2%20.7%18.1%
1 Year109.8%109.8%117.3%113.9%19.7%15.1%
3 Yearn/a223.3%207.7%-5.1%-15.1%
5 Yearn/a353.3%314.9%65.1%37.0%

Long-Term Price Volatility Vs. Market

How volatile is Venus Medtech (Hangzhou)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Venus Medtech (Hangzhou) undervalued compared to its fair value and its price relative to the market?

10.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 2500 (HK$90.65) is trading above our estimate of fair value (HK$55.13)

Significantly Below Fair Value: 2500 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 2500 is unprofitable, so we can't compare its PE Ratio to the HK Medical Equipment industry average.

PE vs Market: 2500 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2500's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2500 is overvalued based on its PB Ratio (10.2x) compared to the HK Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Venus Medtech (Hangzhou) forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

50.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2500 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: 2500 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2500's is expected to become profitable in the next 3 years.

Revenue vs Market: 2500's revenue (46.7% per year) is forecast to grow faster than the Hong Kong market (14.4% per year).

High Growth Revenue: 2500's revenue (46.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2500's Return on Equity is forecast to be high in 3 years time (22.2%)


Next Steps

Past Performance

How has Venus Medtech (Hangzhou) performed over the past 5 years?

30.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2500 is currently unprofitable.

Growing Profit Margin: 2500 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2500's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.7%).


Return on Equity

High ROE: 2500 has a negative Return on Equity (-7.92%), as it is currently unprofitable.


Next Steps

Financial Health

How is Venus Medtech (Hangzhou)'s financial position?


Financial Position Analysis

Short Term Liabilities: 2500's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥415.5M).

Long Term Liabilities: 2500's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥58.4M).


Debt to Equity History and Analysis

Debt Level: 2500's debt to equity ratio (0.03%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 2500's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2500 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2500 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Venus Medtech (Hangzhou) current dividend yield, its reliability and sustainability?

0.007%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2500's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2500's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2500's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2500's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2500's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Venus Medtech (Hangzhou) has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Zeng Min
Executive Chairman of the Board2.17yrsno data11.34%
CN¥ 4.3b
Haiyue Ma
CFO & Joint Company Secretary1.5yrsno datano data
Hou-Sen Lim
COO, CTO & Executive Director2.17yrsno data1.09%
CN¥ 416.4m
Zhenjun Zi
GM & Executive Director8.17yrsno data9.93%
CN¥ 3.8b
Christopher Richardson
Head of U.S. Operations1.5yrsno datano data
Wai Wong
Joint Company Secretaryno datano datano data

1.5yrs

Average Tenure

50yo

Average Age

Experienced Management: 2500's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Zeng Min
Executive Chairman of the Board2.17yrsno data11.34%
CN¥ 4.3b
Hou-Sen Lim
COO, CTO & Executive Director2.17yrsno data1.09%
CN¥ 416.4m
Zhenjun Zi
GM & Executive Director8.17yrsno data9.93%
CN¥ 3.8b
Wing Yu Leung
Vice-Chairwoman of the Board7.58yrsno datano data
Martin Leon
Member of Advisory Boardno datano datano data
Chaim Lotan
Member of Global Advisory Board1yrno datano data
Chi Wai Suen
Independent Non-Executive Director1.5yrsno datano data
Yan Xiao
Chairwoman of the Supervisory Committee2.17yrsno datano data
Wan Yee Lau
Independent Non-executive Director1.5yrsno datano data
Yuk Wu Ting
Independent Non-Executive Director2.17yrsno datano data
Lingling Yang
Shareholders Representative Supervisor2.17yrsno datano data
Scott Lim
Member of Global Advisory Board1yrno datano data

2.2yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 2500's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 2500 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.


Top Shareholders

Company Information

Venus Medtech (Hangzhou) Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Venus Medtech (Hangzhou) Inc.
  • Ticker: 2500
  • Exchange: SEHK
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: HK$38.342b
  • Shares outstanding: 422.97m
  • Website: https://www.venusmedtech.com

Number of Employees


Location

  • Venus Medtech (Hangzhou) Inc.
  • No. 88, Jiangling Road
  • 3rd Floor
  • Hangzhou
  • Zhejiang Province
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2500SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDDec 2019
2500SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesForeign Shares-Foreign ListedHKHKDDec 2019

Biography

Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart v...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 10:23
End of Day Share Price2021/01/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.